Introduction: Dipyrone has been positioned in several countries
as one of the first over-the-counter options for pain management.
Its possible adverse effects are known worldwide; among them,
agranulocytosis is the most lethal, with a mortality of approxi-
mately 10% and an associated risk of 1 per 1,000,000 patients.
Clinical findings, interventions, and outcomes: A case of a
patient who, after 23 days of using dipyrone for pain management,
developed a progressive drop in leukocyte count. Other potential
causes of the event were ruled out. After dipyrone discontinuation,
leukocyte counts returned to their normal values.
Conclusion: The probable diagnosis of granulocytopenia as a
dipyrone-related adverse drug reaction was established. Al-
though rare, dipyrone-related granulocytopenia, may occur in
patients who use this medication for long periods.
Dipyrone-related granulocytopenia. Case report
Audifarma |
| Tiempo de lectura: Min
- Tema: Farmacovigilancia
- Autores: Jorge Enrique Machado-Alba, Leidy Viviana Sánchez-Morales, Luisa Fernanda Rodríguez-Ramírez
- Idiomas: Inglés
- Palabras clave: "Dipirona, Agra- nulocitosis, Farmacovigilancia, Efectos Adversos, Reporte de casoDipyrone, Agranulo- cytosis, Pharmacovigilance, Ad- verse effects, Case Report"
Machado-Alba JE, Sánchez-Morales LV, Rodriguez-Ramirez LF. Dipyrone-related granulocytopenia. Case report. Colombian Journal of Anesthesiology. 2018;46:327-330. Enlace: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-33472018000400327&lng=en&nrm=iso